[Effects of Fuzheng Huayu Capsule on the ratio of TGF-beta1/BMP-7 of chronic viral hepatitis B fibrosis patients of Gan-Shen insufficiency blood-stasis obstruction syndrome].

Abstract

OBJECTIVE:

To observe the effects of Fuzheng Huayu Capsule (FHC) on the liver function, HBV DNA quantization, the ratio of transforming growth factor-beta1/bone morphogenetic protein-7 (TGF-beta1/ BMP-7) of peripheral blood mononuclear cells (PBMCs), HBV DNA YMDD variation, and the liver tissue pathology of chronic viral hepatitis B fibrosis patients of Gan-Shen insufficiency blood-stasis obstruction syndrome (GSIBSOS) on the basis of antiviral treatment by lamivudine.

METHODS:

Eighty chronic viral hepatitis B fibrosis patients of GSBSOS were randomly assigned to two groups. Patients in the control group (43 cases) were treated with lamivudine alone, while those in the treatment group (37 cases) were treated with lamivudine + FHC. The treatment period lasted for 6 months. By the end of treatment lamivudine was continually given to all patients, and patients were followed up for 6 months. Before and after treatment, liver tissue pathology was examined by liver biopsy. The serum HBV DNA quantization, the ratio of TGF-beta1/BMP-7 were determined by fluorescence quantitative polymerase chain reaction (PCR). HBV DNA YMDD variation was tested by the end of follow-ups.

RESULTS:

Better effects were obtained in decreasing the levels of ALT, AST, and HBV DNA after 6 months of treatment in the two groups, with statistical difference when compared with before treatment in the same group, but with no statistical difference between the two groups. At the end of the 6th month follow-up, YMDD variation occurred in 9 cases of the control group and in 5 cases of the treatment group, with statistical difference between the two groups (P < 0.05). FHC could significantly reduce the ratio of TGF-beta1/BMP-7, significantly lower in the treatment group (0.09 vs 0.25, P < 0.05). In the aspect of liver tissue pathological changes, the rates of inflammatory activity over G3 and fibrosis degree S3 in the treatment group were significantly lower than those in the control group (P < 0.05).

CONCLUSIONS:

On the basis antiviral treatment of lamivudine for chronic viral hepatitis B fibrosis patients of BSOS, additional application of FHC could lower the HBV DNA YMDD variation, improve the hepatic inflammation and fibrosis, and exert anti-fibrosis by decreasing the ratio of TGF-beta1/BMP-7.

• Authors: Cui-Lan Tang, Zhou Zhou, Wei-Qun Shi
• Journal: Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine (Zhongguo Zhong Xi Yi Jie He Za Zhi) Vol. 32 Issue 1 Pg. 20-4 (Jan 2012) ISSN: 1003-5370 [Print] China
• PMID: 22500384 (Publication Type: English Abstract, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Antiviral Agents
• BMP7 protein, human
• Bone Morphogenetic Protein 7
• Drugs, Chinese Herbal
• TGFB1 protein, human
• Transforming Growth Factor beta1
• fuzheng huayu
• Lamivudine

Topics

• Adult
• Antiviral Agents (therapeutic use)
• Bone Morphogenetic Protein 7 (metabolism)
• Drugs, Chinese Herbal (pharmacology, therapeutic use)
• Female
• Hepatitis B, Chronic (drug therapy, pathology)
• Humans
• Lamivudine (therapeutic use)
• Leukocytes, Mononuclear (drug effects, metabolism)
• Liver Cirrhosis (drug therapy, pathology)
• Male
• Middle Aged
• Transforming Growth Factor beta1 (metabolism)